Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study.
Journal: EBioMedicine
Published: July 03, 2025
Selective STING stimulation in dendritic cells primes antitumor T cell responses.
Journal: Science immunology
Published: January 13, 2023
Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models.
Journal: International journal of molecular sciences
Published: May 26, 2020
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 28, 2019
Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory.
Journal: Oncoimmunology
Published: June 29, 2018
Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling.
Journal: PloS one
Published: November 04, 2015
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.
Journal: Investigational new drugs
Published: October 17, 2014
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.
Journal: Hepatology (Baltimore, Md.)
Published: November 15, 2013
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 28, 2013
Last Updated: 09/26/2026